Clinical trials: Sdh
Gastrointestinal Stromal Tumors, Sdh
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Funding Source - FDA OOPD FDA-approved products for patients with unresectable or metastatic GIST include therapies such as imatinib and sunitinib.
- Conditions
- Gastrointestinal Stromal Tumors, Sdh, GIST, Cancer
- Trial name
- NCT03556384
- Testing
- Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Adam Burgoyne, MD, PhD